FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PhaseRx's Free Cash Flow for the
three
months ended in Sep. 2017 was $-2.57 Mil. PhaseRx's Revenue for the
three
months ended in Sep. 2017 was $0.00 Mil. Therefore, PhaseRx's FCF Margin % for the quarter that ended in Sep. 2017 was 0.00%.
The historical rank and industry rank for PhaseRx's FCF Margin % or its related term are showing as below:
PZRXQ's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -141.025 * Ranked among companies with meaningful FCF Margin % only.
PhaseRx FCF Margin % Historical Data
The historical data trend for PhaseRx's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PhaseRx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhaseRx's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhaseRx's FCF Margin % distribution charts can be found below:
* The bar in red indicates where PhaseRx's FCF Margin % falls into.
PhaseRx FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
PhaseRx's FCF Margin for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhaseRx FCF Margin % Related Terms
Thank you for viewing the detailed overview of PhaseRx's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PZRXQ has been successfully added to your 